High-dose angiotensin II receptor blocker (ARB), olmesartan, monotherapy versus combination therapy of normal-dose olmesartan with selective aldosterone antagonist, selara, treatment on central blood pressure in patients with ischemic heart disease: a single-center, prospective, randomized, open-labes study - High-dose angiotensin II receptor blocker (ARB), olmesartan, monotherapy versus combination therapy of normal-dose olmesartan with selective aldosterone antagonist, selara, treatment on central blood pressure in patients with ischemic heart disease

Showa University Northern Yokohama Hospital.0 个研究点目标入组 60 人开始时间: 2013年5月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) myocardial infarction 2) subjects who already have Olmesartan or Eplerenone at the entry 3) history of allergy against these drugs or similar compounds 4) subjects whose serum potassium level is over 5.0mEq/L 5) Diabetes mellitus patients whose albumin excretion rates > 300mg/24hours 6) subjects with moderate renal dysfunction (eGFR <50 ml/min/1.73m2) 7) hepatic dysfunction (Child-Pugh C) 8) subjects taking potassium supplements, potassium saving diuretics, or strong CYP3A4-inhibitors (Itraconazol, Ritonavir, and Nelfinavir) 9) Pregnancy 10) Additionally, patient who judged that doctor in charge is improper (For example, FH or secondary hyperlipidemia, tumor, administering cyclosporine, drug abuse or alcoholism, hypothyroidism and inherited stripe disease or the family medical histories, previous history of medicinal muscle disorder.)

发起方

Showa University Northern Yokohama Hospital.